Clearmind Medicine, Inc. (CMND)
0.92
-0.05
(-4.83%)
USD |
NASDAQ |
Sep 14, 16:00
0.92
0.00 (0.00%)
After-Hours: 16:59
Clearmind Medicine Enterprise Value : -12.06M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | -12.06M |
| September 10, 2026 | -12.03M |
| September 09, 2026 | -11.86M |
| September 08, 2026 | -11.92M |
| September 04, 2026 | -11.64M |
| September 03, 2026 | -10.48M |
| September 02, 2026 | -10.16M |
| September 01, 2026 | -10.21M |
| August 31, 2026 | -9.969M |
| August 28, 2026 | -10.36M |
| August 27, 2026 | -10.25M |
| August 26, 2026 | -10.44M |
| August 25, 2026 | -10.46M |
| August 24, 2026 | -10.53M |
| August 21, 2026 | -10.40M |
| August 20, 2026 | -10.42M |
| August 19, 2026 | -10.03M |
| August 18, 2026 | -9.926M |
| August 17, 2026 | -10.08M |
| August 14, 2026 | -10.14M |
| August 13, 2026 | -10.16M |
| August 12, 2026 | -10.59M |
| August 11, 2026 | -10.68M |
| August 10, 2026 | -10.70M |
| August 07, 2026 | -10.63M |
| Date | Value |
|---|---|
| August 06, 2026 | -10.38M |
| August 05, 2026 | -10.36M |
| August 04, 2026 | -10.46M |
| August 03, 2026 | -10.63M |
| July 31, 2026 | -10.51M |
| July 30, 2026 | -11.86M |
| July 29, 2026 | -12.02M |
| July 28, 2026 | -12.02M |
| July 27, 2026 | -11.86M |
| July 24, 2026 | -11.87M |
| July 23, 2026 | -11.82M |
| July 22, 2026 | -11.81M |
| July 21, 2026 | -11.84M |
| July 20, 2026 | -11.60M |
| July 17, 2026 | -11.53M |
| July 16, 2026 | -11.48M |
| July 15, 2026 | -11.65M |
| July 14, 2026 | -11.54M |
| July 13, 2026 | -11.48M |
| July 10, 2026 | -11.44M |
| July 09, 2026 | -11.40M |
| July 08, 2026 | -11.37M |
| July 07, 2026 | -11.35M |
| July 06, 2026 | -11.12M |
| July 02, 2026 | -11.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | 4.654M |
| NervGen Pharma Corp. | 171.34M |
| Milestone Pharmaceuticals, Inc. | 93.24M |
| Lexaria Bioscience Corp. | 2.636M |
| Target Group, Inc. (Canada) | 11.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9073M |
| Total Expenses (Quarterly) | 0.9073M |
| EPS Diluted (Quarterly) | -0.5734 |
| Earnings Yield | -9.58K% |
| Normalized Earnings Yield | -13222.16 |